Skip Navigation

Annals of Oncology 2006 17(Supplement 7):vii5-vii9; doi:10.1093/annonc/mdl940
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ricevuto, E.
Right arrow Articles by Marchetti, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ricevuto, E.
Right arrow Articles by Marchetti, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters

E. Ricevuto1,*, Z. C. Di Rocco1, T. Sidoni1, C. Ficorella1, G. Porzio1, P. Pujol2, B. Adamo3, O. Majorana4 and P. Marchetti1,5

1 Medical Oncology, Department of Experimental Medicine, University, L'Aquila, Italy; 2 Service de Génétique Mèdicale, INSERM 54, CHU de Montpellier, France; 3 Department of Medical Oncology, University of Messina, Italy; 4 Department of Medical Oncology, University of Palermo, Italy; 5 Department of Medical Oncology, IDI-IRCCS, Rome, Italy

* Correspondence to: Dr E. Ricevuto, Università degli Studi di L'Aquila, Dipartimento di Medicina Sperimentale, Via Vetoio, Coppito II 67100, L'Aquila, Italia. Tel: +39-0862-433582; Fax: +39-0862-433523; E-mail: enrico.ricevuto{at}univaq.it

Recently, chemoprevention trials have demonstrated the efficacy of preventive medical treatment (PMT) in reducing breast cancer (BC) detection rates in at-risk affected and unaffected women selected according to clinical and/or familial risk criteria, particularly with the use of tamoxifen (TAM). Major concerns limiting the routine use of TAM are the questionable benefit/risk ratio and poor patient compliance, which justify the studies undertaken to determine the efficacy of aromatase inhibitors (AIs) with respect to TAM. Issues such as therapy duration, impact on survival, incidence of side-effects and which subsets benefit most from treatment, still remain unsolved. Therefore, only ER+ BC patients are routinely subjected to PMT, independently of their BRCA1/2 status, using adjuvant hormonal therapy. More attention must be focused towards BRCA1/2 carriers as they are probably the women at highest risk of developing BC, in which available data remain controversial and in which hormone-therapy might be important. Hence, at-risk women (affected patients or unaffected women) should be carefully evaluated for inclusion into highly selected preventive clinical trials aimed at evaluating PMT independently of, or according to, BC predisposition status (unknown, positive or negative BRCA1/BRCA2 status) and with respect to menopausal status. BC patients, harboring a BRCA1/2 predisposition, may represent the best subset for extended adjuvant treatment, useful as PMT, simultaneously. Only the evolving differentiation of categories of at-risk women will allow physicians to discriminate PMT in a highly selective manner.

Key words: Breast cancer, at-risk women, prevention, aromatase inhibitors, tamoxifene


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.